---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094542"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-08-12T12:35:13+00:00"
generated_at: "2026-08-12T12:40:09.948673+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aprea Q2 2026: net loss $3.6M, cash $41.2M, APR-1051 enrollment accelerating

## Summary
- Cash $41.2M at June 30, 2026 vs $14.6M at Dec 31, 2025; runway into Q1 2028.
- Net loss $3.6M ($0.07/share) on 53.5M shares vs $3.2M ($0.53/share) on 6.1M shares in Q2 2025.
- APR-1051 Phase 1 trial sites expand 3 to 10; enrollment 6-10 patients/month by Q4 2026; next data at Q4 2026 medical meeting.
- Plans to advance APR-1051 in USC and Cyclin E-overexpressing PROC; combinations in HPV+ head/neck and colorectal cancer.
- $30M private placement closed Q1 2026; ATRN-119 study closed, combinations under discussion.

## SEC filing metadata
- accession: 0001104659-26-094542
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-08-12T12:35:13+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/0001104659-26-094542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094542
- JSON: https://secwatch.observer/filing/0001104659-26-094542.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.